"published earlier this month in the Journal of the American Medical Association, explored the effects of MM120 - described by pharmaceutical company MindMed as "a proprietary, pharmaceutically optimized form of LSD" - on generalized anxiety disorder.What did these researchers find? As the paper's authors phrased it, "In participants with moderate to severe [generalized anxiety disorder], a single dose of MM120 produced a dose-dependent reduction in anxiety.""
"In an article on the study and its results, NPR's Jon Hamilton noted that the dosing was accompanied by, well, what you'd expect if you took a psychedelic substance: hallucinations. Interestingly, the study also shows that 10.3% of participants who received the placebo experienced "illusion, pseudo-hallucination and visual hallucination."Among the questions that remain, Hamilton reports, are the effects of the environment where the studies took place on the results."
Between 1950 and 1965, around 40,000 patients were prescribed lysergic acid to treat conditions such as alcoholism, schizophrenia and PTSD. Recent clinical research has documented LSD's potential to treat psychological conditions. Researchers tested MM120, described by MindMed as a pharmaceutically optimized form of LSD, in participants with moderate to severe generalized anxiety disorder and observed that a single dose produced dose-dependent reductions in anxiety, with 100‑ and 200‑microgram doses outperforming placebo. Dosing commonly produced hallucinations, and 10.3% of placebo recipients reported illusion or visual hallucination. The influence of study setting on outcomes remains an open question.
Read at InsideHook
Unable to calculate read time
Collection
[
|
...
]